Mutation Analysis in Ten Cases With PNPLA1 ‐Nonsyndromic Epidermal Differentiation Disorder: Evidence of a Founder Effect
The Journal of Dermatology · 2026-06 · 53 (6) · 896-904
DOI: 10.1111/1346-8138.70252 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Dermatology, online erschienen am 10.04.2026. Verfasst von Yunran Peng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Founder Effect, Ichthyosis, Lamellar, Lipase. Die Arbeit nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Autosomal recessive congenital ichthyosis (ARCI) belongs to a heterogeneous group of nonsyndromic epidermal differentiation disorders (nEDD). Variants in PNPLA1 , which encodes a transacylase essential for the formation of epidermal lipid barrier, underlie ARCI10. This study aims to unveil the underlying genetic basis in ten Chinese cases diagnosed with ARCI, and to determine the origin of a prevalent variant. Ten cases, encompassing twelve patients with ARCI, were recruited for this study. Whole‐exome sequencing combined with Sanger sequencing was used to detect the underlying variants. Haplotype analysis using flanking highly polymorphic SNPs was used to trace the origin of the c.1300delG variant in the PNPLA1 gene. All patients developed generalized fine scales and erythema shortly after birth. Marked phenotypic heterogeneity was observed among the affected individuals, leading to diagnosis of either generalized or localized nEDD. In total, we detected three recurrent variants (c.1300delG, p.A434Hfs*22; c.434 T > C, p.Ile145Thr; c.488C > T, p.Pro163Leu) and five novel variants (c.205 + 1G > A, splicing; c.74C > T, p.Ser25Phe; c.473G > A, p.Cys158Tyr; c.731A > G, p.Tyr244Cys; c.1318C > T, p.Arg440*) in PNPLA1 . The c.1300delG variant, prevalent in 7 unrelated ARCI cases, was associated with a common haplotype. Furthermore, we presented the beneficial effect of secukinumab treatment in one of our patients. Our findings suggest that the c.1300delG variant is a highly prevalent variant in Chinese PNPLA1 ‐associated nEDD patients, and indicate that the recurrent variant may originate from a common ancestor in southern China, suggesting a regional founder effect. The observed response with secukinumab in one patient suggests that it might represent a potential therapeutic option for PNPLA1 ‐nEDD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dermatology Hospital, Southern Medical University, Guangzhou, China.
- The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China.
- Shenzhen Center for Chronic Disease Control, Shenzhen Dermatology Hospital, Shenzhen, China.
- Department of General Dermatology, Guangzhou Dermatology Hospital, Guangzhou, China.
ORCID-Profile: Quan Chen, Zhimiao Lin
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Peng, Y., Guan, Y., Lv, K., Yang, C., Chen, Q., Wang, H., & Lin, Z. (2026). Mutation Analysis in Ten Cases With PNPLA1 ‐Nonsyndromic Epidermal Differentiation Disorder: Evidence of a Founder Effect. The Journal of Dermatology, 53(6), 896-904. https://doi.org/10.1111/1346-8138.70252
Vancouver
Peng Y, Guan Y, Lv K, Yang C, Chen Q, Wang H, et al. Mutation Analysis in Ten Cases With PNPLA1 ‐Nonsyndromic Epidermal Differentiation Disorder: Evidence of a Founder Effect. The Journal of Dermatology. 2026;53(6):896-904. doi:10.1111/1346-8138.70252
BibTeX
@article{Peng2026,
author = {Peng, Yunran and Guan, Yang and Lv, Kunlun and Yang, Chao and Chen, Quan and Wang, Huijun and Lin, Zhimiao},
title = {Mutation Analysis in Ten Cases With PNPLA1 ‐Nonsyndromic Epidermal Differentiation Disorder: Evidence of a Founder Effect},
journal = {The Journal of Dermatology},
year = {2026},
volume = {53},
number = {6},
pages = {896--904},
doi = {10.1111/1346-8138.70252}
}
EUVIMED